Improving Clinical Management and Patient-Reported Outcomes Among Patients with Rheumatoid Arthritis in China via Real-world Evidence (IMPROVE Study): A Multicenter Prospective Cohort Study

被引:0
作者
Jiang, Nan [1 ,2 ,3 ,4 ]
Liu, Dongzhou [5 ,6 ]
Duan, Xinwang [7 ]
Wu, Lijun [8 ]
Liu, Yi [9 ]
Zhu, Hao [10 ]
Zhang, Yanjie [10 ]
Li, Mengtao [1 ,2 ,3 ,4 ]
Tian, Xinping [1 ,2 ,3 ,4 ]
Zeng, Xiaofeng [1 ,2 ,3 ,4 ]
机构
[1] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Peking Union Med Coll, Dept Rheumatol & Clin Immunol, Beijing, Peoples R China
[2] Minist Sci & Technol, Natl Clin Res Ctr Dermatol & Immunol Dis NCRC DID, Beijing, Peoples R China
[3] Peking Union Med Coll Hosp, State Key Lab Complex Severe & Rare Dis, Beijing, Peoples R China
[4] Minist Educ, Key Lab Rheumatol & Clin Immunol, Beijing, Peoples R China
[5] Jinan Univ, Shenzhen Peoples Hosp, Clin Med Coll 2, Dept Rheumatol & Immunol, Shenzhen, Guangdong, Peoples R China
[6] Southern Univ Sci & Technol, Affiliated Hosp 1, Shenzhen, Guangdong, Peoples R China
[7] Nanchang Univ, Dept Neurol, Affiliated Hosp 2, Nanchang, Jiangxi, Peoples R China
[8] Xinjiang Uygur Autonomous Reg Peoples Hosp, Dept Rheumatol, Urumqi, Xinjiang Uygur, Peoples R China
[9] Sichuan Univ, West China Hosp, Dept Rheumatol & Immunol, Chengdu, Sichuan, Peoples R China
[10] Eli Lilly China, Suzhou, Jiangsu, Peoples R China
关键词
Disease activity; Disease management; Improvement; Patient-reported outcomes; Rheumatoid arthritis; DISEASE-ACTIVITY; GLOBAL ASSESSMENT; REMISSION; BURDEN; RECOMMENDATIONS; BARICITINIB; CRITERIA;
D O I
10.1007/s12325-025-03179-7
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Introduction: Patient-reported outcomes (PROs) help to understand rheumatoid arthritis (RA) from patients' perspective and play an important role in RA management. This study aims to describe the PRO changes over 6 months among patients with RA in China and explore the relationships between PROs and RA disease activity. Methods: This multicenter prospective cohort study enrolled patients with RA aged >= 18 years. At enrollment, patients were dichotomized into remission/low disease activity (LDA) and moderate-to-high disease activity (MDA/HDA) based on Disease Activity Score-28 with C-Reactive Protein (DAS28-CRP). Only patients with MDA/HDA (DAS28-CRP >= 3.2) were followed for 6 months. PROs included pain, fatigue, morning stiffness, Patients' Global Assessment (PtGA), disability, work productivity, and activity impairment. Disease activity measures included DAS28-CRP, DAS28-Erythrocyte Sedimentation Rate (DAS28-ESR), Clinical Disease Activity Index (CDAI), and Simplified Disease Activity Index (SDAI). Results: A total of 872 patients were enrolled: 520 patients in remission/LDA and 352 in MDA/HDA. In MDA/HDA patients, pain decreased significantly from enrollment at month 1 (p < 0.0001), month 3 (p < 0.0001), and month 6 (p = 0.0094). Fatigue improved significantly at month 3 (p = 0.0073). Other PROs, including morning stiffness, PtGA, disability, work productivity, and activity impairment, also improved. Patients who achieved remission/LDA had significant faster decline in pain, fatigue, PtGA, and work productivity compared to those who did not. Pain was positively correlated with disease activity measures at months 1, 3, and 6, while fatigue was positively associated with disease activity measures at months 3 and 6 only. Morning stiffness, PtGA, and disability correlated with disease activity at months 1 and 3. Conclusions: Patients with RA with MDA/HDA in China experienced significant improvement in pain and fatigue over 6 months. Improvement in DAS28-CRP was associated with faster improvement in certain PROs. While disease activity correlated with some PROs, they did not fully capture patient experience, highlighting the importance of PROs in RA management.
引用
收藏
页码:2906 / 2921
页数:16
相关论文
共 43 条
[21]  
National Institute of Environmental Health Sciences, HLTH ASSESSMENT QUES
[22]  
Pelechas E., 2019, ILLUSTRATED HDB RHEU, P45, DOI [10.1007/978-3-030-03664-5_3, 10.1007/978-3-030-03664-53, DOI 10.1007/978-3-030-03664-5_3]
[23]   Pathogenesis of autoimmune disease [J].
Pisetsky, David S. .
NATURE REVIEWS NEPHROLOGY, 2023, 19 (08) :509-524
[24]   Impact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activity [J].
Pope, Janet ;
Bingham, Clifton O., III ;
Fleischmann, Roy M. ;
Dougados, Maxime ;
Massarotti, Elena M. ;
Wollenhaupt, Juergen ;
Duncan, Benjamin ;
Coteur, Geoffroy ;
Weinblatt, Michael E. .
ARTHRITIS RESEARCH & THERAPY, 2015, 17
[25]   In-depth bibliometric analysis and current scientific mapping research in the context of rheumatoid arthritis pharmacotherapy [J].
Radu, Andrei-Flavius ;
Bungau, Simona Gabriela ;
Negru, Paul Andrei ;
Marcu, Mihai Florin ;
Andronie-Cioara, Felicia Liana .
BIOMEDICINE & PHARMACOTHERAPY, 2022, 154
[26]   2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis [J].
Singh, Jasvinder A. ;
Saag, Kenneth G. ;
Bridges, S. Louis, Jr. ;
Akl, Elie A. ;
Bannuru, Raveendhara R. ;
Sullivan, Matthew C. ;
Vaysbrot, Elizaveta ;
McNaughton, Christine ;
Osani, Mikala ;
Shmerling, Robert H. ;
Curtis, Jeffrey R. ;
Furst, Daniel E. ;
Parks, Deborah ;
Kavanaugh, Arthur ;
O'Dell, James ;
King, Charles ;
Leong, Amye ;
Matteson, Eric L. ;
Schousboe, John T. ;
Drevlow, Barbara ;
Ginsberg, Seth ;
Grober, James ;
St Clair, E. William ;
Tindall, Elizabeth ;
Miller, Amy S. ;
McAlindon, Timothy .
ARTHRITIS CARE & RESEARCH, 2016, 68 (01) :1-25
[27]   Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force [J].
Smolen, Josef S. ;
Breedveld, Ferdinand C. ;
Burmester, Gerd R. ;
Bykerk, Vivian ;
Dougados, Maxime ;
Emery, Paul ;
Kvien, Tore K. ;
Navarro-Compan, M. Victoria ;
Oliver, Susan ;
Schoels, Monika ;
Scholte-Voshaar, Marieke ;
Stamm, Tanja ;
Stoffer, Michaela ;
Takeuchi, Tsutomu ;
Aletaha, Daniel ;
Louis Andreu, Jose ;
Aringer, Martin ;
Bergman, Martin ;
Betteridge, Neil ;
Bijlsma, Hans ;
Burkhardt, Harald ;
Cardiel, Mario ;
Combe, Bernard ;
Durez, Patrick ;
Fonseca, Joao Eurico ;
Gibofsky, Alan ;
Gomez-Reino, Juan J. ;
Graninger, Winfried ;
Hannonen, Pekka ;
Haraoui, Boulos ;
Kouloumas, Marios ;
Landewe, Robert ;
Martin-Mola, Emilio ;
Nash, Peter ;
Ostergaard, Mikkel ;
Ostor, Andrew ;
Richards, Pam ;
Sokka-Isler, Tuulikki ;
Thorne, Carter ;
Tzioufas, Athanasios G. ;
van Vollenhoven, Ronald ;
de Wit, Martinus ;
van der Heijde, Desiree .
ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 (01) :3-15
[28]   Discordance between patient and physician assessments of global disease activity in rheumatoid arthritis and association with work productivity [J].
Smolen, Josef S. ;
Strand, Vibeke ;
Koenig, Andrew S. ;
Szumski, Annette ;
Kotak, Sameer ;
Jones, Thomas V. .
ARTHRITIS RESEARCH & THERAPY, 2016, 18
[29]   Treating rheumatoid arthritis to target: recommendations of an international task force [J].
Smolen, Josef S. ;
Aletaha, Daniel ;
Bijlsma, Johannes W. J. ;
Breedveld, Ferdinand C. ;
Boumpas, Dimitrios ;
Burmester, Gerd ;
Combe, Bernard ;
Cutolo, Maurizio ;
de Wit, Maarten ;
Dougados, Maxime ;
Emery, Paul ;
Gibofsky, Alan ;
Gomez-Reino, Juan Jesus ;
Haraoui, Boulos ;
Kalden, Joachim ;
Keystone, Edward C. ;
Kvien, Tore K. ;
McInnes, Iain ;
Martin-Mola, Emilio ;
Montecucco, Carlomaurizio ;
Schoels, Monika ;
van der Heijde, Desiree .
ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (04) :631-637
[30]   Recently diagnosed rheumatoid arthritis patients benefit from a treat-to-target strategy: results from the DREAM registry [J].
Steunebrink, Laura M. M. ;
Vonkeman, Harald E. ;
ten Klooster, Peter M. ;
Hoekstra, Monique ;
van Riel, Piet L. C. M. ;
van de Laar, Mart A. F. J. .
CLINICAL RHEUMATOLOGY, 2016, 35 (03) :609-615